Survey of carboplatin dosing strategies in oncology practices

被引:4
作者
Blankenship, Patrick [1 ]
Waddell, J. Aubrey [2 ,3 ]
机构
[1] Blount Mem Hosp, Emergency Dept, Maryville, TN 37804 USA
[2] Univ Tennessee, Coll Pharm, Knoxville, TN USA
[3] Blount Mem Hosp, Maryville, TN 37804 USA
关键词
Area under the curve; carboplatin dosing; carboplatin equations; GLOMERULAR-FILTRATION-RATE; FORMULAS;
D O I
10.1331/JAPhA.2013.12053
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: To identify variations in carboplatin dose calculations at oncology institutions and practices in the southeastern United States. Methods: 500 surveys were mailed to oncology practices in the southeastern United States to assess variations in carboplatin doses. The survey sought to determine assumptions that are made regarding carboplatin calculations and if different carboplatin doses result when participants are given the same data and patient characteristics. Results: The survey had a response rate of 12% (n = 56 of 467). The majority of responses used actual serum creatinine and actual body weight. The Cockcroft-Gault creatinine clearance formula was used most commonly. The doses calculated in the case example of an AUC (area under the curve) 6 dose of carboplatin ranged from 110 to 1,811 mg (mean 987 mg, median 963 mg). We determined a correct dose of 721 mg for the case example. Conclusion: The majority of responses to the case example indicated overdosing of carboplatin. Participants provided inconsistent doses, and their interpretation of the variables in the equations varied. More research is needed, and efforts should be made to have a universal modified Calvert formula with standardized assumptions to achieve consistent dosing across practices.
引用
收藏
页码:420 / U183
页数:5
相关论文
共 10 条
[1]   Evaluation of glomerular filtration rate estimation by Cockcroft-Gault, Jelliffe, Wright and Modification of Diet in Renal Disease (MDRD) formulae in oncology patients [J].
Ainsworth, N. L. ;
Marshall, A. ;
Hatcher, H. ;
Whitehead, L. ;
Whitfield, G. A. ;
Earl, H. M. .
ANNALS OF ONCOLOGY, 2012, 23 (07) :1845-1853
[2]  
Busse Tom, 2003, Clin J Oncol Nurs, V7, P104
[3]   CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].
CALVERT, AH ;
NEWELL, DR ;
GUMBRELL, LA ;
OREILLY, S ;
BURNELL, M ;
BOXALL, FE ;
SIDDIK, ZH ;
JUDSON, IR ;
GORE, ME ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756
[4]  
Cathomas R, 2007, J CLIN ONCOL, V25
[5]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[6]   Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies [J].
de Lemos, Mario L. ;
Hsieh, Teresa ;
Hamata, Linda ;
Levin, Adeera ;
Swenerton, Ken ;
Djurdjev, Ognjenka ;
Vu, Thanh ;
Hu, Francis ;
Conklin, James ;
Taylor, Suzanne C. Malfair .
GYNECOLOGIC ONCOLOGY, 2006, 103 (03) :1063-1069
[7]   Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥27 or Cachexia [J].
Herrington, JD ;
Tran, HT ;
Riggs, MW .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (02) :241-247
[8]  
Hood and Drug Administration, CARB DOS
[9]  
HUTSON PR, 2000, P AN M AM SOC CLIN, V19, pA187
[10]  
Waddell JA, 2000, HOSP PHARM, V35, P914